Search
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing … [A235668,A235730] Aducanumab is a recombinant antibody derived from patients with slow or absent cognitive decline, and phase 1b clinical trial data have shown patients treated with aducanumab show a reduction
Naloxone
go.drugbank.com/drugs/DB01183ApprovedInvestigationalVet approved[L33734] Kits commonly include the supplies necessary to treat an overdose in a non-medical setting such as alcohol swabs, syringes, a rescue breathing mask, and instructions for use. … [L33714,L33719] Naloxone was granted FDA approval on 13 April 1971.[L33709]
Mixtures: TILIDIN HEXAL COMP D-PUMPE, TARGIN ® 20 MG / 10 MG TABLETAS DE LIBERACIÓN PROLONGADAProducts: NALOKSON HIDROKLORUR ENJ.10AMP(D)(ETyrosine
go.drugbank.com/drugs/DB00135ApprovedInvestigationalNutraceuticalTyrosine is a non-essential amino acid. In animals it is synthesized from [phenylalanine]. It is also the precursor of [epinephrine], thyroid hormones, and melanin.
Mixtures: Appformin-D, Appbutamone-DOzenoxacin
go.drugbank.com/drugs/DB12924ApprovedAs of December 11, 2017 the FDA approved Ferrer Internacional S.A.' … Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationalIn March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease ( … a short peptide linker.
Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational[L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20 … Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively.
Levomefolic acid
go.drugbank.com/drugs/DB11256ApprovedLevomefolate is approved as a food additive and is designated a GRAS (generally regarded as safe) compound [L773]. … It is available commercially as a crystalline form of the calcium salt (Metafolin(R)), which has the stability required for use as a supplement [A19276].
Mixtures: BumP DHA, BumP DHAIrofulven
go.drugbank.com/drugs/DB05786InvestigationalPhase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe. … A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].
Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215107, A215112, A215117, A215127] Cedazuridine is a fluorinated tetrahydrouridine derivative specifically designed to inhibit CDA and facilitate oral administration of hypomethylating agents. … [A215082, A215092, A215097] Hypomethylating agents such as [decitabine] and [azacitidine] are used to treat MDS through inducing DNA hypomethylation and apoptosis of cancerous cells.